Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 5.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,233,693 shares of the company's stock after selling 384,701 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 1.64% of Standard BioTools worth $6,732,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of LAB. Mirabella Financial Services LLP purchased a new position in shares of Standard BioTools during the fourth quarter valued at $5,478,000. Royce & Associates LP grew its holdings in shares of Standard BioTools by 136.8% during the 4th quarter. Royce & Associates LP now owns 1,455,503 shares of the company's stock valued at $2,547,000 after acquiring an additional 840,951 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Standard BioTools by 80.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 554,203 shares of the company's stock valued at $970,000 after acquiring an additional 247,332 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Standard BioTools by 9.3% during the 4th quarter. Northern Trust Corp now owns 2,875,160 shares of the company's stock valued at $5,032,000 after acquiring an additional 243,522 shares in the last quarter. Finally, GM Advisory Group LLC bought a new stake in shares of Standard BioTools in the 4th quarter valued at approximately $350,000. Hedge funds and other institutional investors own 53.74% of the company's stock.
Standard BioTools Stock Performance
Shares of LAB traded down $0.07 during trading hours on Monday, hitting $1.28. 1,843,821 shares of the company were exchanged, compared to its average volume of 1,951,861. The company has a market cap of $486.17 million, a PE ratio of -3.66 and a beta of 1.54. The firm's 50 day moving average is $1.11 and its 200-day moving average is $1.29. Standard BioTools Inc. has a 52 week low of $0.92 and a 52 week high of $2.41.
About Standard BioTools
(
Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Featured Stories
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
